Clinical trial
Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals
NCT00218413 · Nabi Biopharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00218413 |
|---|---|
| Title | Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals |
| Official title | A Phase 2 Study to Assess Safety and Immunogenicity of Five Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) Administered to Smokers |
| Lead sponsor | Nabi Biopharmaceuticals, Industry |
| Collaborators | National Institute on Drug Abuse (NIDA) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Smoking Cessation, Tobacco Use Cessation |
| Intervention type | Biological |
| Interventions | NicVAX |
| Enrollment | 51 |
| Start date | Oct 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Jan 12, 2017 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: